RA
LAB icon

Royce & Associates’s Standard BioTools LAB Stock Holding History

Royce & Associates’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.72M Buy
4,525,333
+1,519,804
+51% +$1.44M 0.03% 540
2026
Q1 		$2.76M Buy
3,005,529
+120,000
+4% +$145K 0.03% 545
2025
Q4 		$3.69M Buy
2,885,529
+80,810
+3% +$109K 0.04% 513
2025
Q3 		$3.65M Buy
2,804,719
+167,598
+6% +$220K 0.04% 517
2025
Q2 		$3.16M Buy
2,637,121
+636,618
+32% +$706K 0.03% 541
2025
Q1 		$2.16M Buy
2,000,503
+545,000
+37% +$765K 0.02% 579
2024
Q4 		$2.55M Buy
1,455,503
+840,951
+137% +$1.57M 0.02% 595
2024
Q3 		$1.19M Buy
614,552
+310,321
+102% +$608K 0.01% 708
2024
Q2 		$538K Buy
+304,231
New +$744K 0.01% 785
2019
Q4 		– Sell
-122,400
Closed -$567K – 1157
2019
Q3 		$567K Sell
122,400
-63,000
-34% -$496K 0.01% 881
2019
Q2 		$2.28M Hold
185,400
– – 0.02% 695
2019
Q1 		$2.46M Buy
185,400
+37,000
+25% +$390K 0.02% 681
2018
Q4 		$1.28M Buy
+148,400
New +$1.16M 0.01% 824
2013
Q4 		– Sell
-3,300
Closed -$72K – 1458
2013
Q3 		$72K Hold
3,300
– – ﹤0.01% 1378
2013
Q2 		$58K Buy
+3,300
New +$57.9K ﹤0.01% 1368

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's LAB Position: Q2 2026 in Review

Royce & Associates increased its Standard BioTools (LAB) stake by 51% in Q2 2026, buying an estimated $1.44M and bringing the position to 4,525,333 shares worth $3.72M. The position accounts for 0.03% of the portfolio, ranked #540.

Royce & Associates first reported a position in LAB in Q2 2013 and has held it in 15 quarters since. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Royce & Associates held 4,525,333 shares of Standard BioTools worth $3.72M as of Q2 2026.
  • Royce & Associates bought 1,519,804 Standard BioTools shares in Q2 2026, an estimated $1.44M.
  • Standard BioTools made up 0.03% of Royce & Associates's portfolio in Q2 2026, its #540 holding.
  • Royce & Associates first reported a position in Standard BioTools in Q2 2013 and has held it in 15 quarters since.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.